ASPIRE BIOPHARMA HOLDINGS, INC.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | — | $6.2K | — | — | — | — |
| Cost of Revenue | — | $6.3K | — | — | — | — |
| Gross Profit | — | $-116 | — | — | — | — |
| Gross Margin | — | -1.9% | — | — | — | — |
| Operating Expenses | ||||||
| Research & Development | — | $923.9K | $144.4K | — | — | — |
| SG&A Expense | — | $17.6M | $940.4K | $1.3M | $976.3K | $25.5K |
| Operating Income | — | $-19.4M | $-1.2M | — | — | — |
| Operating Margin | — | -312,016.9% | — | — | — | — |
| Interest Expense | — | — | $891.6K | $9.0K | — | — |
| Pretax Income | — | $-24.5M | $-1.3M | — | — | — |
| Income Tax Expense | — | — | $1.0K | — | — | — |
| Net Income | — | $-24.5M | $-1.3M | $4.5M | $3.3M | $-25.5K |
| Net Margin | — | -394,725.1% | — | — | — | — |
| EPS (Basic) | — | — | — | — | — | — |
| EPS (Diluted) | — | $-16.38 | $-0.95 | — | — | — |
| Shares Outstanding (Basic) | 5.0M | 1.5M | 1.4M | — | — | — |
| Shares Outstanding (Diluted) | 5.0M | 1.5M | 1.4M | — | — | — |
| Dividends Per Share | — | — | — | — | — | — |